INSIGHTS ON ENTERPRISE SOLUTIONS

• Your Journey To GMP With Emphasis On Linker Payload Development

  Develop lower risk strategies with our insights into the key considerations you need to factor in when conjugating your linker payload to its antibody in our review of the pros and cons of semi-synthetic and synthetic linker payloads.

• Custom Designed Linker-Payload Synthesis And Bioconjugation

  Achieve ADC development with an integrated approach to linker-payload design and synthesis. Learn how custom synthesis and a bioconjugation strategy accelerate candidate selection and GMP manufacturing.

• Identification Of New Classes Of Maytansinoid Payloads For ADCs

  See how a successful collaboration led to the design of novel, cell-permeable maytansine-based payloads for ADCs. These new tubulin inhibitors were engineered to enhance the critical "bystander killer effect."

• Essential Insights Into Linker Chemistry For ADCs

  The linker is key to an ADC's success, influencing stability and targeted drug release. Explore the evolution of linker chemistry, from cleavable mechanisms to site-specific conjugation, and learn why rigorous assessment is critical.

• Optimizing CMC Strategy For Successful Scale-Up

  10/22/2025

  In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) share advice on developing CMC strategies in a way that strengthens manufacturability through careful assay development and collaboration with CDMOs.

• Developing Analytical Methods For Advanced ADCs

  10/22/2025

  Advanced molecules, especially ADCs with novel constructs, require extensive characterization testing. In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) discuss the nuances of analytical methodology for advanced ADCs and emphasize the importance of potency assays. They also share their thoughts on how much CMC development companies should aim to do internally before working with development partners.

• CMC Challenges Facing Next-Generation ADCs

  10/22/2025

  In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) weigh in on the biggest challenges to ADC development, particularly navigating geopolitical tensions in a time of increasingly global manufacturing operations.

• Game-Changing CLD Platforms: Strategies, Technologies, Workflows

  10/21/2025

  Selecting the right cell line platform is complex. Learn how flexible strategies, integrated technologies, and expert workflows enable high productivity, rapid timelines, and a de-risked path to clinical success.